188 related articles for article (PubMed ID: 11785073)
1. [Diferelin treatment of primary local and generalized cancer of the prostate].
Kolesnikov GP; Rusakov IG; Shaplygin LV; Voznesenskiĭ SA; Bystrov AA
Urologiia; 2001; (6):17-9. PubMed ID: 11785073
[No Abstract] [Full Text] [Related]
2. Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer.
Krongrad A; Brady J; Rodriguez RJ
South Med J; 1997 Apr; 90(4):460-1. PubMed ID: 9114847
[No Abstract] [Full Text] [Related]
3. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
Smith MR; Zietman AL; Finkelstein JS; Wu CL
N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
[No Abstract] [Full Text] [Related]
4. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
Daskivich TJ; Oh WK
Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
[TBL] [Abstract][Full Text] [Related]
5. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Berenguer Sánchez A
Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
[No Abstract] [Full Text] [Related]
6. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
7. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
8. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
Matveev BP; Bukharkin BV
Urologiia; 2001; (6):20-1. PubMed ID: 11785074
[No Abstract] [Full Text] [Related]
9. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
10. A case of orbital metastasis from prostatic carcinoma as an initial symptom.
Isshiki S; Cho S; Matsuno D; Sato N; Furuya Y
Hinyokika Kiyo; 2007 Mar; 53(3):193-5. PubMed ID: 17447492
[TBL] [Abstract][Full Text] [Related]
11. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
[TBL] [Abstract][Full Text] [Related]
12. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
Akyol F; Ozyigit G; Selek U; Karabulut E
Eur Urol; 2005 Jul; 48(1):40-5. PubMed ID: 15967250
[TBL] [Abstract][Full Text] [Related]
13. High dose hook effect in serum total and free prostate specific antigen in a patient with metastatic prostate cancer.
Furuya Y; Cho S; Ohta S; Sato N; Kotake T; Masai M
J Urol; 2001 Jul; 166(1):213. PubMed ID: 11435864
[No Abstract] [Full Text] [Related]
14. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
15. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration.
Procopio G; Guadalupi V; Giganti MO; Mariani L; Salvioni R; Nicolai N; Capone F; Valdagni R; Bajetta E
BJU Int; 2011 Jul; 108(2):223-7. PubMed ID: 21078047
[TBL] [Abstract][Full Text] [Related]
16. Editorial comment.
Türkeri L
Can J Urol; 2010 Jun; 17(3):5169. PubMed ID: 20566008
[No Abstract] [Full Text] [Related]
17. False elevations in prostate-specific antigen levels affecting patient management.
Kummar S; Shafi NQ
Clin Adv Hematol Oncol; 2004 Sep; 2(9):599-601; discussion 602. PubMed ID: 16163243
[No Abstract] [Full Text] [Related]
18. Biochemical remission after resection of prostate cancer lung metastasis.
Chao DH; Higgins JP; Brooks JD
Urology; 2004 Mar; 63(3):584-5. PubMed ID: 15028469
[TBL] [Abstract][Full Text] [Related]
19. [Quality of life of patients with prostatic cancer under hormonal therapy].
Aliaev IuG; Aslamazov EG; Demidko IuL
Urologiia; 2010; (1):46, 48-51. PubMed ID: 20891045
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy.
Behrakis P; Koutsilieris M
Anticancer Res; 1997; 17(3A):1517-8. PubMed ID: 9179189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
